Effect of Ultrashort-Acting β-Blockers on Mortality in Patients With Sepsis With Persistent Tachycardia Despite Initial Resuscitation A Systematic Review and Meta-analysis of Randomized Controlled Trials

被引:66
|
作者
Hasegawa, Daisuke [1 ]
Sato, Ryota [2 ]
Prasitlumkum, Narut [3 ]
Nishida, Kazuki [4 ]
Takahashi, Kunihiko [5 ]
Yatabe, Tomoaki [1 ]
Nishida, Osamu [1 ]
机构
[1] Fujita Hlth Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Toyoake, Aichi, Japan
[2] Cleveland Clin, Resp Inst, Dept Crit Care Med, Cleveland, OH 44106 USA
[3] Univ Calif Riverside, Sch Med, Dept Cardiol, Riverside, CA 92521 USA
[4] Nagoya Univ, Grad Sch Med, Ctr Adv Med & Clin Res, Dept Biostat Sect, Nagoya, Aichi, Japan
[5] Tokyo Med & Dent Univ, M&D Data Sci Ctr, Dept Biostat, Tokyo, Japan
关键词
beta-blocker; esmolol; landiolol; sepsis; sepsis-associated tachycardia; SEPTIC SHOCK; HEART-RATE; ATRIAL-FIBRILLATION; NOREPINEPHRINE; DEFINITIONS; OUTCOMES; ESMOLOL; MULTICENTER; GUIDELINES; LANDIOLOL;
D O I
10.1016/j.chest.2021.01.009
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Historically, beta-blockers have been considered to be relatively contraindicated for septic shock because they may cause cardiac suppression. On the other hand, there is an increasing interest in the use of beta-blockers for treating patients with sepsis with persistent tachycardia despite initial resuscitation. RESEARCH QUESTION: Do ultrashort-acting beta-blockers such as esmolol and landiolol improve mortality in patients with sepsis with persistent tachycardia despite initial resuscitation? STUDY DESIGN AND METHODS: This was a systematic review and meta-analysis. We searched MEDLINE, Cochrane Central Register of Controlled Trials, and Embase for randomized controlled trials (RCTs) that compared the mortality of patients with sepsis and septic shock treated with esmolol or landiolol. We updated our search on April 20, 2020. Two independent reviewers assessed whether titles and abstracts met the following eligibility criteria: (1) RCT, (2) patients with sepsis and septic shock >= 18 years of age, and (3) treatment with either esmolol/landiolol or placebo/no interventions. Two authors independently extracted selected patient and study characteristics and outcomes. The results of all analyses are presented using random effect models. RESULTS: Seven RCTs with a pooled sample size of 613 patients were included. Of these, six RCTs with 572 patients reported 28-day mortality. Esmolol or landiolol use in patients with sepsis and septic shock was significantly associated with lower 28-day mortality (risk ratio, 0.68; 95% CI, 0.540.85; P <.001). Unimportant heterogeneity was observed (I-2 = 31%). The absolute risk reduction and number of patients to be treated to prevent one death were 18.2% and 5.5, respectively. INTERPRETATION: The use of ultrashort-acting beta-blockers such as esmolol and landiolol in patients with sepsis with persistent tachycardia despite initial resuscitation was associated with significantly lower 28-day mortality.
引用
收藏
页码:2289 / 2300
页数:12
相关论文
共 50 条
  • [41] Effect of Immediate Administration of Antibiotics in Patients With Sepsis in Tertiary Care: A Systematic Review and Meta-analysis
    Johnston, Amy N. B.
    Park, Joon
    Doi, Suhail A.
    Sharman, Vicki
    Clark, Justin
    Robinson, Jemma
    Crilly, Julia
    CLINICAL THERAPEUTICS, 2017, 39 (01) : 190 - 202
  • [42] The effect of goal-directed therapy on mortality in patients with sepsis - earlier is better: a meta-analysis of randomized controlled trials
    Gu, Wan-Jie
    Wang, Fei
    Bakker, Jan
    Tang, Lu
    Liu, Jing-Chen
    CRITICAL CARE, 2014, 18 (05)
  • [43] Effect of integrative medicines on 28-day mortality from sepsis: a systematic review and network meta-analysis
    Xiaoxia, Q.
    Cheng, C.
    Minjian, W.
    Huilin, C.
    Zhen, L.
    Yuedong, Y.
    Xingyu, Z.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (02) : 664 - 677
  • [44] Mortality Benefit From the Passive Leg Raise Maneuver in Guiding Resuscitation of Septic Shock Patients: A Systematic Review and Meta-Analysis of Randomized Trials
    Azadian, Moosa
    Win, Suyee
    Abdipour, Amir
    Kim, Carolyn Krystal
    Nguyen, H. Bryant
    JOURNAL OF INTENSIVE CARE MEDICINE, 2022, 37 (05) : 611 - 617
  • [45] The Effects of Restrictive Fluid Resuscitation on the Clinical Outcomes in Patients with Sepsis or Septic Shock: A Meta-Analysis of Randomized-Controlled Trials
    Shahnoor, Husna
    Divi, Rachana
    Palle, Lokeshwar Raaju Addi
    Sharma, Ashutosh
    Contractor, Bianca
    Krupanagaram, Santoshi
    Batool, Saima
    Ali, Neelum
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [46] Omega-3 supplementation in patients with sepsis: a systematic review and meta-analysis of randomized trials
    Lu, Clara
    Sharma, Sunjay
    McIntyre, Lauralyn
    Rhodes, Andrew
    Evans, Laura
    Almenawer, Saleh
    Leduc, Lori
    Angus, Derek C.
    Alhazzani, Waleed
    ANNALS OF INTENSIVE CARE, 2017, 7
  • [47] Prolonged versus intermittent β-lactam infusion in sepsis: a systematic review and meta-analysis of randomized controlled trials
    Yang Zhao
    Bin Zang
    Qian Wang
    Annals of Intensive Care, 14
  • [48] The Effect of Combination Therapy on Mortality and Adverse Events in Patients with Staphylococcus aureus Bacteraemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Ye, Chao
    Wang, Chunjiang
    Li, Zuojun
    Li, Xin
    Pan, Juan
    Liu, Liang
    Wang, Zhaohui
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (04) : 2643 - 2660
  • [49] Omega-3 supplementation in patients with sepsis: a systematic review and meta-analysis of randomized trials
    Clara Lu
    Sunjay Sharma
    Lauralyn McIntyre
    Andrew Rhodes
    Laura Evans
    Saleh Almenawer
    Lori Leduc
    Derek C. Angus
    Waleed Alhazzani
    Annals of Intensive Care, 7
  • [50] Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Chaugai, Sandip
    Meng, Wen Yeng
    Sepehry, Amir Ali
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2016, 21 (04) : 388 - 404